Lumevoq (lenadogene nolparvovec)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- lenadogene nolparvovec
- Company
- GenSight Biologics S.A.
- Status
- Application withdrawn
- Therapeutic area
- Optic Atrophy, Hereditary, Leber
- Designations
- Orphan
- Application
- EMEA/H/C/005047
- ATC
- S01
- Official record
- www.ema.europa.eu
Indication
Lumevoq (lenadogene nolparvovec) is indicated for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by a confirmed G11778A mutation in the ND4 mitochondrial gene (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Follow Lumevoq
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.